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SUMMARY Transforming growth factor β (TGF-β) and interleukin 10 (IL-10) are 
two anti-inflammatory cytokines that are implicated in the pathogenesis of ur-
ticaria. The goal of this study was to examine the possible association of poly-
morphisms of TGF-β and IL-10 genes with susceptibility to chronic idiopathic 
urticaria (CIU). This study was conducted on 90 patients with CIU. Polymerase 
chain reaction (PCR) was done to determine the genotype at 5 polymorphic 
sites; TGF-β (codon10C/T and codon25G/C) and IL-10 (-1082G/A, -819C/T, and 
-592C/A). The C allele at codon 25 of TGF-β was more prevalent in CIU patients 
compared to controls (OR = 9.5, 95% CI = 5.4-16.8, P<0.001). Genotypes of CT 
and CG at 10 and 25 codons of TGF-β gene, respectively, and AG, CT, and CA for 
loci of -1082, -819, and -592 of IL-10 gene were significantly higher in CIU pa-
tients (P<0.001). In haplotype analysis, frequency of TGF-β haplotypes differed 
between patients with CIU and controls; CC haplotype was overrepresented, 
while CG and TG haplotypes were underrepresented (P<0.001). These results 
suggest that TGF-β and IL-10 genetic variability could contribute to susceptibil-
ity to CIU. Additionally, patients with CIU seem to have genotypes leading to 
high production of TGF-β and IL-10. 
KeYwoRdS: interleukin 10 (IL-10); transforming growth factor β (TGF-β); 
chronic idiopathic urticaria; single nucleotide polymorphism (SNP)
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InTRodUCTIon
Chronic idiopathic urticaria (CIU) is characterized 
by itching wheals lasting for more than six weeks 
with unknown etiology. The pathophysiology of 
CIU is complex, and the diagnosis is made when no 
identifiable cause has been detected for pruritic le-
sions (1,2). Mast cell activation has been suggested 
to be the pivotal mechanism behind CIU. Histamine 
and leukotrienes mediate inflammation and cause 
persistence of cutaneous wheals. For initiation and 
maintenance of the inflammatory process, cytokines 
are the key factor. Cytokines are implicated not only 
in recruitment of inflammatory cells to the target site, 
but also in triggering the cell signaling that leads to 
release of histamine and eicosanoids (3,4).
Mast cell activation leads to not only the release 
of histamine and leukotrienes, but also production of 
proinflammatory cytokines that promote inflamma-
tory response (5). Previously, our research group dem-
onstrated that polymorphisms in promoter region of 
proinflammatory cytokines are associated with CIU 
(6). On the other hand, regulatory mechanisms can 
suppress the inflammatory process by inhibition of 
either mast cells or other cell types contributing to 
the inflammation. Transforming growth factor β1 
(TGF-β1) has been demonstrated to play an impor-
tant role in homeostasis of mast cells (7). TGF-β1 pro-
motes apoptosis of mast cells (8), suppresses expres-
sion of both of the Fc-epsilon receptor I (FcεRI) and 
immunoglobin E (Ig-E) on mast cell surface (9), and 
attenuates mediator release from mast cells (8). Inter-
leukin 10 (IL-10), another anti-inflammatory cytokine, 
exerts similar effects such as inhibition of expression 
of FcεRI on mast cells and suppression of inflamma-
tory mediator release (10, 11). Furthermore, IL-10 is 
able to induce apoptosis of not only mast cells, but 
also other inflammatory cells (12). It has been shown 
that patients with CIU have decreased serum levels of 
IL-10, compared to healthy controls (13). On the other 
hand, some patients with CIU showed significantly 
increased levels of IL-10 in cutaneous samples or sera 
compared with the healthy population (8-12). Altera-
tion in cytokine profile of patients with CIU may be of 
importance in the pathophysiology of CIU.
Reduced levels of anti-inflammatory cytokines 
may be caused by reduced expression of cytokine 
genes. Transcription initiation is the main step of gene 
expression regulation, and polymorphisms at the 
promoter region may lead to altered gene expression 
(14). We hypothesized that genetic variability in the 
promoter region of IL-10 as well as polymorphisms 
in the coding region of TGF-β could contribute to 
the risk of CIU. Accordingly, in this study we aimed to 
investigate allele frequencies, genotypes, and haplo-
types of TGF-β and IL-10 in patients with CIU in com-
parison with controls. 
PATIenTS And MeThodS
Participants and study design 
This hospital-based case-control study was com-
prised of 90 patients with CIU. Diagnosis of CIU was 
made based on international guidelines, thus includ-
ing patients with at least 2 occurrences of wheals for 
more than 6 weeks in the absence of any identifiable 
cause (15). The patients were randomly selected from 
the outpatient clinic of allergy and immunology in 
the Children’s Medical Center Hospital, the Pediatrics 
Center of Excellence in Tehran, Iran. One hundred 
and forty healthy subjects were also randomly se-
lected (16). A detailed history and physical examina-
tion were taken prior to enrolment to ensure that all 
participants met the selection criteria. Subjects with 
physical urticaria, cold urticaria, urticaria vasculitis, 
and drug induced urticaria were excluded from the 
patient group. Subjects who were suspected to have 
chronic urticaria, allergic disease, or autoimmunities 
were not included as controls. No matching was done 
  Table 1. Allele frequency of TGF-β and IL-10 polymorphic sites in patients with CIU as compared with controls
Cytokine Position Alleles Controls CIU oR (95% CI) P value
TGF-β Codon 10 C 131 (47.5) 83 (46) 1 (ref )
T 145 (52.5) 97 (53.8) 1.1 (0.7-1.6) 0.85
TGF-β Codon 25 G 255 (92.4) 101 (56.1) 1 (ref )
C 21 (7.6) 79 (43.8) 9.5 (5.4-16.8) <0.001
IL-10 -1082 A 181 (64.6) 101 (56.7) 1 (ref )
G 99 (35.4) 77 (43.2) 1.39 (0.93-2.09) 0.11
IL-10 -819 C 199 (71.1) 116 (65.9) 1 (ref )
T 81 (28.9) 60 (34) 1.27  (0.83-1.94) 0.29
IL-10 -592 C 199 (71.1) 120 (67.4) 1 (ref )
A 81 (28.9) 58 (32.6) 1.19 (0.77-1.82) 0.47
Frequencies are expressed as number (percent).
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in terms of age and gender, but all the participants 
had the same ethnicity. This study was approved by 
the Institutional Review Board of Tehran University of 
Medical Sciences. All of the participants received de-
tailed information regarding the aim and protocol of 
study and signed informed consent forms.
 dnA extraction and genotyping
Blood samples were taken from all of the partici-
pants and preserved with Ethylene-diamine-tetra-
acetic acid (EDTA) as anticoagulant. Genomic DNA 
was isolated from peripheral blood leukocytes using 
phenol chloroform extraction. Polymerase chain re-
action (PCR) with sequence specific primers was used 
for genotyping (PCR-SSP kit, Heidelberg University, 
Heidelberg, Germany), as explained before (16). PCR 
products were detected with 2% agarose gel electro-
phoresis and visualized using an ultraviolet (UV) trans-
illuminator. The polymorphic sites tested in this study 
included TGF-β [codon10 or +869C/T (rs1982073) 
and codon25 or +915G/C (rs1800471)] and IL-10 [-
1082G/A (rs1800896), -819C/T (rs1800871), -592C/A 
(rs1800872)]. 
Statistical analysis
All of the analyses were performed using the Epi 
Info statistical software (version 6.2, World Health Or-
ganization, Geneva, Switzerland). Required sample 
size was calculated according to previously published 
methods with α = 0.05, β = 0.2 (power = 80%) and 
the ratio of 3:2 for controls:cases (17). Direct gene 
counting was used to estimate allele, genotype, and 
haplotype frequencies. Estimated frequencies were 
compared between patients with CIU and controls 
using the chi square test or Fisher’s exact test as ap-
propriate. A 95% confidence interval (95% CI) was es-
timated for allele, genotype, and haplotype frequen-
cies in patients with CIU as compared with controls. 
To adjust 95% CIs for sex, the Bonferroni method was 
used. All the tests were two sided, and probability of 
less than 0.05 was considered significant.
ReSUlTS  
Allele analysis 
All of the allele frequencies are in line with the 
Hardy-Weinberg equilibrium. Among the tested 
polymorphic sites, frequency of C allele at codon 25 
of the TGF-β gene was significantly higher in patients 
with CIU, as compared to controls (43.8% versus 7.6%, 
P<0.001). Other allele frequencies did not differ be-
tween CIU patients and healthy controls (Table 1). 
Genotyping results
Genotype analysis revealed that the following 
genotypes were overrepresented in patients with 
CIU: TGF-β genotypes of CT and CG for 10 and 25 co-
dons and IL-10 genotypes of AG, CT, and CA for loci 
of -1082, -819, and -592, respectively (P<0.001). TT at 
codon 10 of TGF-β, CC at codon25 of TGF-β, and AG at 
-1082, CT at -819, and AA at -592 in promoter of IL-10 
were significantly lower in CIU patients. Patients with 
CIU were more heterozygous for evaluated geno-
types. Detailed frequencies regarding each genotype 
are outlined in Table 2.
  Table 2. Genotype frequency of TGF-β and IL-10 polymorphic sites in patients with CIU as compared with 
   controls
Cytokine  Position Alleles Controls CIU oR (95% CI) P value
TGF-β Codon 10 CC 20 (14.5) 0 1 (ref )
CT 91 (65.9) 83 (92.2) 1.1 (0.7-1.6) <0.001
TT 27 (19.6) 7 (7.7) 0.35 (0.13-0.89) 0.02
TGF-β Codon 25 GG 119 (86.2) 11 (12) 1 (ref )
GC 17 (12.3) 79 (87.7) 51.1 (21.3-126) <0.001
CC 2 (1.5) 0 0.0 (0.0-6.3) <0.001
IL-10 -1082 AA 53 (37.8) 16 (17.9) 1 (ref )
AG 75 (53.6) 69 (77.5) 2.99 (1.58-5.69) <0.001
GG 12 (8.6) 4 (4.42) 0.50 (0.13-1.75) 0.36
IL-10 -819 CC 71 (50.7) 30 (34) 1 (ref )
 CT 57 (40.7) 56 (63.6) 2.55 (1.42-4.59) 0.001
TT 12 (8.6) 2 (2.27) 0.25 (0.04-1.21) 0.09
IL-10 -592 CC 71 (50.7) 32 (35.9) 1 (ref )
CA 57 (40.7) 56 (62.9) 2.47 (1.38-4.43) 0.002
AA 12 (8.6) 1 (1.12) 0.55 (0.30-0.97) 0.04
Frequencies are expressed as number (percent).
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CG 110 (39.9) 83 (25.46) 0.5 (0.4-0.7) <0.001
TG 145 (52.5) 90 (27.6) 0.3 (0.2-0.5) <0.001
CC 21 (7.6) 74 (22.69) 3.6 (2.1-6.2) <0.001





GCC 99 (35.4) 73 (35.6) 1.0 (0.7-.5) 0.97
ACC 100 (35.7) 82 (40) 1.2 (0.8-.8) 0.38
ATA 81 (28.9) 50 (24.4) Reference -
Frequencies are expressed as number (percent).
haplotype analysis
None of the possible haplotypes of ACA, GCA, 
ATC, GTC, and GTA of IL-10 polymorphic sites of -1082, 
-819, and -592 were observed in participants. GCC, 
ACC, and ATA haplotypes for IL-10 polymorphic sites 
were equally distributed between patients with CIU 
and controls. All of the possible haplotypes of TGF-β 
(C/T at codon 10 and G/C at codon 25) significantly 
differed in CIU patients as compared with controls; 
CC haplotype was overrepresented, while CG and TG 
haplotypes were underrepresented. Detailed haplo-
type analysis is outlined in Table 3.
dISCUSSIon
CIU patients suffer from recurrent chronic urticar-
ial lesions without any specific cause. Genetic predis-
position may be of high importance in development 
of CIU, and our study is the first to show the associa-
tion of the TGF-β coding region and IL-10 promoter 
polymorphisms with CIU. The results of this study 
provide evidence that genetic variability in TGF-β 
and IL-10 genes contributes to susceptibility to CIU. 
Two polymorphic sites in the TGF-β gene [codon10C/
T at +869 (rs1982073) and codon25G/C at +915 
(rs1800471)] and three polymorphic sites in promoter 
region of IL-10 gene [-1082G/A (rs1800896), -819C/T 
(rs1800871), -592C/A (rs1800872)] were investigated 
in patients with CIU and healthy subjects as controls. 
The strongest association was found in codon25G/C 
(rs1800471) in the coding sequence of TGF-β gene on 
chromosome 19q13.1. Carriers of minor C allele and 
GC genotype were significantly higher in patients 
with CIU, with OR of 9.5 (95% CI, 5.4-16.8) and 51.1 
(95% CI, 21.3-126), respectively. These polymorphisms 
in the TGF-β first exon lead to substitution of leucine 
(T) with proline (C) at codon10 and arginine (G) for 
proline (C) at codon25. It has been suggested that 
this genetic variability may affect TGF-β production; 
GG genotype at rs1800471 (+915G/C) in combina-
tion with TT genotype at rs1982073 (+869T/C) result 
in higher production of TGF-β (18). Another study on 
patients with gastric cancer demonstrated that carri-
ers of GC genotype at rs1800471 had the highest se-
rum level of TGF-β as compared to other genotypes 
(19). CC genotype is associated with the lowest pro-
duction of TGF-β, whether at rs1800471 or 1982073 
polymorphic sites, while GG genotype leads to the 
high TGF-β production. Homozygous genotype of 
CC that leads to low TGF-β1 production and homo-
zygous genotypes of GG or TT leading to high pro-
duction of TGF-β1 were significantly lower in patients 
with CIU; No patients with CIU had CC genotype; GG 
genotype at rs1800471 was found only in 12% of pa-
tients with CIU as compared with 86.2% of controls; 
TT genotype at rs1982073 was found in 7.7% of pa-
tients with CIU as compared with 19.6% of healthy 
subjects (P<0.001). As with the higher carriage of C 
allele in patients with, heterozygous genotypes that 
are associated with high TGF-β1 production were sig-
nificantly higher in patients with CIU. In interpreting 
these findings regarding TGF-β polymorphisms, eth-
nicity cannot be an affecting factor because a previ-
ous study on Iranians showed that the minor C allele 
was only present in 7-10% of population without any 
significant differences form Caucasians from Greece, 
England, and Finland and African-Americans (16).Par-
ticipants in our study were in the same age-range and 
ORs were adjusted with respect to gender. Controls 
were healthy, and patients with CIU were free of any 
comorbidity such as autoimmunity, cancer, or chron-
ic disease that could be considered a confounder. 
Hence, the significant association of TGF-β polymor-
phism with CIU seems not to be affected with any 
confounding factor. 
Park et al. demonstrated that promoter polymor-
phism of TGF-β -509C/T is associated with aspirin in-
tolerant chronic urticaria development. In that study 
in Korean patients, TT genotype frequencies were 
significantly higher in aspirin intolerant patients with 
Table 3. Haplotype frequency of TGF-β and IL-10 polymorphic sites in patients with CIU as compared with 
controls
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chronic urticarial, whereas TGF-β1 serum levels tend-
ed to be lower (20). In patients with atopic dermatitis, 
Arkwright et al. (21) found that among IL-10 -1082G/
A (rs1800896), TGF-β codon10C/T (rs1982073), and 
TGF-β (rs1800471) codon25G/C polymorphic sites, 
only C allele at rs1800471 was significantly higher in 
patients (OR = 4.8, 95% CI = 2.4-9.7). In our findings, 
patients with CIU also had higher C allele frequencies 
but with greater OR of 9.5 and 95% CI of 5.4 to 16.8. 
Our study also found higher frequency of GC geno-
type in patients with CIU that is consistent with the 
study by Arkwrigh et al. (21) in which 40% of patients 
with atopic dermatitis had GC genotype as compared 
with 12% of controls (P=0.001). GC genotype at co-
don25G/C (rs1800471) was previously demonstrated 
to be higher in patients with asthma (22) and com-
mon variable immunodeficiency (23) in Iranian popu-
lation. Inappropriate immune response and imbal-
ance in cytokine profile are implicated in both the 
diseases. 
The TGF-β gene encodes TGF-β1 that belongs 
to the TGF-β superfamily. TGF-β1 is a cytokine with 
diverse effects on cell function, differentiation, and 
proliferation. TGF-β1 also plays a crucial role in skin 
biology; TGF-β1 regulates homeostasis of keratino-
cytes, antigen presenting cells, and inflammatory 
cells. TGF-β1 is implicated in cutaneous wound heal-
ing (24), clearance of apoptotic cells from skin tissue 
(25), maintenance of a healthy skin barrier function 
(26), and interference with neoplastic cell adhesion 
and growth in skin (27). Additionally, TGF-β1 had 
contrasting roles in development of skin hypersen-
sitivity. Over-expression of TGF-β1 by keratinocytes, 
as well as exogenous addition of TGF-β to culture 
of skin explants, leads to induction of inflammation, 
infiltration of plasmacytoid dendritic cells to dermis 
(28), and increase in eotaxin production by dermal fi-
broblasts (29). On the other hand, Smad3-/- mice that 
lack intracellular signaling mediator of TGF-β showed 
increased expression of proinflammatory and T-help-
er2 cytokines and developed contact hypersensitivity 
(30). TGF-β1 also acts as an anti-inflammatory cytokine 
in skin mainly via inhibition of mast cell survival and 
function (9,31,32). However, the pathophysiology of 
CIU has not been well defined. Mast cells seem to be 
pivotal factors in CIU (1,3). Mast cells are major cells 
responsible for histamine release and urticarial lesion 
formation in CIU. Increase in mast cell release, espe-
cially during active rather than remission stage of CIU, 
is commonly seen. Ferrer et al. demonstrated that CIU 
patients have higher serum tryptase levels compared 
with healthy controls and even atopic patients free 
of CIU. They also found that this marker of mast cell 
degranulation is increased during the active stage of 
CIU (33). Anti-histamines help relieve the symptoms 
in these patients; however, some patients do not re-
spond adequately to this treatment, indicating com-
plexity of CIU pathogenesis (1,3). Immunoregulatory 
cytokines such as TGF-β1 and IL-10 inhibit T-helper2 
cytokines as well as mast cell survival, FCεRI expres-
sion, binding to Ig-E, and mediator release from mast 
cells (8-12, 32). 
IL-10 is an anti-inflammatory cytokine that is se-
creted by macrophages and T lymphocytes. IL-10 in-
hibits proinflammatory cytokine production and has 
inhibitory effects on mast cells (34). It has been previ-
ously shown that patients with CIU have lower serum 
levels of IL-10 compared with the healthy population 
(13). By contrast, some studies showed significantly 
increased levels of IL-10 in cutaneous samples or 
in the sera of patients with CIU compared with the 
healthy population (8-12,32). It is not yet understood 
whether this increase in IL-10 is a consequence or 
compensatory response. Polymorphisms in the IL-10 
gene (located on chromosome 1q31-32) can affect 
expression of IL-10. Changes in promoter region se-
quence alter the affinity of proteins involving in tran-
scription and finally alter the level of gene product. 
All reported polymorphic sites in the promoter of IL-
10 were investigated in participants of our study. No 
significant difference was found in terms of allele and 
haplotype frequencies in patients with as compared 
with controls, while, heterozygous genotypes were 
significantly higher in all loci in the patient group. Ad-
ditionally, only GCC, ATA and ACC were observed in 
participants out of all possible haplotypes. This may 
be explained by a strong linkage disequilibrium that 
is in contrast with TGF-β polymorphic sites in which 
linkage disequilibrium is incomplete (35). Alleles of 
G at -1082G/A, T at -819C/T, and A at -592C/A are as-
sociated with higher production of IL-10 in compari-
son with their counterparts (36). All aforementioned 
alleles were higher in patients with CIU in our study, 
but these differences were not statistically significant. 
This is an unexpected finding, since we expected to 
observe higher frequency of low producing alleles 
and genotypes in patients with CIU. Interestingly, 
Palikhe et al. found that T allele at -819C/T is higher in 
aspirin intolerant patients with chronic urticaria (37). 
Picconi et al. (38) found that levels of IL-10 as well as 
tumor necrosis factor-α, macrophage inflammatory 
protein-1α and chemokine (C-C motif ) ligand-5 (also 
CCL5) were higher in CIU patients, while IL-2 and in-
terferon-γ were reduced. They suggested increased 
level of IL-10 could be a secondary phenomenon 
hampering the inflammation. However, the results of 
our study indicate that patients with CIU have a high 
IL-10 producing genetic background, and increased 
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levels of IL-10 would be a primary rather than a com-
pensatory phenomenon in CIU. Accordingly, the au-
thors suggest conducting further studies on patients 
with CIU to elucidate theinterplay of different groups 
of cytokines in the development of the disease.  
Some studies suggested that IL-10 polymorphism 
frequencies may be affected by ethnic differences, 
since C allele at -819 was the most common allele in 
Asians, while in Caucasians from Europe T was the 
most common allele (39). Iranians showed similar 
allele frequencies as Caucasians at all polymorphic 
sites of the IL-10 gene (16).Furthermore, Palikhe et al. 
(37) found that the T allele at -819C/T was the most 
common allele in the Korean population. Thus, ethnic 
differences could not have affected the results of our 
study. The study benefited from proper design (case-
control) and power of 80% to find the association be-
tween genetic polymorphism in immunoregulatory 
cytokine genes with CIU. All the participants were 
unrelated and of the same ethnicity, and no devia-
tion from Hardy-Weinberg equilibrium was observed. 
However, a limiting factor was the absence of mea-
surement of IL-10 and TGF-β1 levels in serum or gene 
expression using luciferase assay. 
ConClUSIon 
Further studies are needed to draw firmer conclu-
sions regarding the genetic background of patients with 
CIU and the role of immunoregulatory cytokines in CIU. 
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